182 related articles for article (PubMed ID: 22740986)
1. Epithelial cell culture models for the prevention and therapy of clinical breast cancer (Review).
Telang N; Katdare M
Oncol Lett; 2012 Apr; 3(4):744-750. PubMed ID: 22740986
[TBL] [Abstract][Full Text] [Related]
2. Preclinical in vitro models from genetically engineered mice for breast and colon cancer (Review).
Telang N; Katdare M
Oncol Rep; 2011 May; 25(5):1195-201. PubMed ID: 21399881
[TBL] [Abstract][Full Text] [Related]
3. Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells.
Katdare M; Osborne M; Telang NT
Int J Oncol; 2002 Oct; 21(4):809-15. PubMed ID: 12239620
[TBL] [Abstract][Full Text] [Related]
4. Novel cell culture models for prevention of human breast cancer (Review).
Katdare M; Osborne MP; Telang NT
Int J Oncol; 2003 Mar; 22(3):509-15. PubMed ID: 12579302
[TBL] [Abstract][Full Text] [Related]
5. Cell culture model for colon cancer prevention and therapy: an alternative approach to animal experimentation.
Telang N; Katdare M
ALTEX; 2007; 24(1):16-21. PubMed ID: 17361317
[TBL] [Abstract][Full Text] [Related]
6. Anti-proliferative and pro-apoptotic effects of rosemary and constituent terpenoids in a model for the HER-2-enriched molecular subtype of clinical breast cancer.
Telang N
Oncol Lett; 2018 Oct; 16(4):5489-5497. PubMed ID: 30214619
[TBL] [Abstract][Full Text] [Related]
7. Putative cancer-initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer.
Telang N
Oncol Lett; 2015 Dec; 10(6):3840-3846. PubMed ID: 26788219
[TBL] [Abstract][Full Text] [Related]
8. The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy.
Murray AS; Hyland TE; Sala-Hamrick KE; Mackinder JR; Martin CE; Tanabe LM; Varela FA; List K
Oncogene; 2020 Oct; 39(41):6421-6436. PubMed ID: 32868877
[TBL] [Abstract][Full Text] [Related]
9. Gap junctions as targets for cancer chemoprevention and chemotherapy.
Trosko JE; Ruch RJ
Curr Drug Targets; 2002 Dec; 3(6):465-82. PubMed ID: 12448698
[TBL] [Abstract][Full Text] [Related]
10. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
11. Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor-positive clinical breast cancer.
Telang NT; Li G; Sepkovic DW; Bradlow HL; Wong GY
Mol Med Rep; 2012 Jan; 5(1):22-8. PubMed ID: 21971582
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of aberrant proliferation and induction of apoptosis in HER-2/neu oncogene transformed human mammary epithelial cells by N-(4-hydroxyphenyl)retinamide.
Jinno H; Steiner MG; Mehta RG; Osborne MP; Telang NT
Carcinogenesis; 1999 Feb; 20(2):229-36. PubMed ID: 10069458
[TBL] [Abstract][Full Text] [Related]
13. Targeting the HER/EGFR/ErbB family to prevent breast cancer.
Howe LR; Brown PH
Cancer Prev Res (Phila); 2011 Aug; 4(8):1149-57. PubMed ID: 21816844
[TBL] [Abstract][Full Text] [Related]
14. SHON is a novel estrogen-regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy.
Jung Y; Abdel-Fatah TM; Chan SY; Nolan CC; Green AR; Ellis IO; Li L; Huang B; Lu J; Xu B; Chen L; Ma RZ; Zhang M; Wang J; Wu Z; Zhu T; Perry JK; Lobie PE; Liu DX
Cancer Res; 2013 Dec; 73(23):6951-62. PubMed ID: 24296488
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract][Full Text] [Related]
16. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
[TBL] [Abstract][Full Text] [Related]
17. Novel cell culture model for prevention of carcinogenic risk in familial adenomatous polyposis syndrome.
Telang N; Katdare M
Oncol Rep; 2009 Apr; 21(4):1017-21. PubMed ID: 19288003
[TBL] [Abstract][Full Text] [Related]
18. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer.
Lott ST; Chen N; Chandler DS; Yang Q; Wang L; Rodriguez M; Xie H; Balasenthil S; Buchholz TA; Sahin AA; Chaung K; Zhang B; Olufemi SE; Chen J; Adams H; Band V; El-Naggar AK; Frazier ML; Keyomarsi K; Hunt KK; Sen S; Haffty B; Hewitt SM; Krahe R; Killary AM
PLoS Med; 2009 May; 6(5):e1000068. PubMed ID: 19536326
[TBL] [Abstract][Full Text] [Related]
19. Patient-Derived Breast Cancer Tissue Cultures for Anti-Endocrine Drug Assays.
Domenici G; Trindade G; Estrada MF; Cartaxo AL; Alves PM; André S; Brito C
Methods Mol Biol; 2022; 2535():11-31. PubMed ID: 35867219
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial prevention of carcinogenic risk in a model for familial colon cancer.
Telang N; Katdare M
Oncol Rep; 2007 Apr; 17(4):909-14. PubMed ID: 17342335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
